[TAB]
1) The Diabetes Control and Complications Trial Research Group. The effect
of intensive treatment of diabetes on the development and progression of long-term
complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86
2) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control
with sulphonylureas or insulin compared with conventional treatment and risk of
complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131
):837-53
3) Monnier L, Colette C, Boegner C, et al. Continuous glucose monitoring in
patients with type 2 diabetes: Why? When? Whom? Diabetes Metab 2007;33(4):247-52
4) Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute
glucose fluctuations compared with sustained chronic hyperglycemia in patients with
type 2 diabetes. JAMA 2006;295(14):1681-7
5) Hirsch IB, Abelseth J, Bode BW, et al. Sensor-augmented insulin pump therapy:
results of the first randomized treat-to-target study. Diabetes Technol Ther
2008;10(5):377-83
6) Ceriello A. The glucose triad and its role in comprehensive glycaemic
control: current status, future management. Int J Clin Pract 2010;64(12):1705-11
7) Beck RW, Buckingham B, Miller K, et al. Factors predictive of use and of
benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care
2009;32(11):1947-53
8) Anderson J, Effect on glycemic control by short- and long-term use of
continuous glucose monitoring in clinical practice. J Diabetes Sci Technol
2011;5(6):1472-8
9) Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time
continuous glucose monitoring: results from a 12-week observational study. Diabetes
Technol Ther 2007;9(3):203-10
10) Chico A, Vidal-Ríos P, Subirà M, Novials A. The continuous glucose
monitoring system is useful for detecting unrecognized hypoglycemias in patients with
type 1 and type 2 diabetes but is not better than frequent capillary glucose
measurements for improving metabolic control. Diabetes Care 2003;26(4):1153-7
11) Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels
to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using
a 7-day continuous glucose sensor. Diabetes Care 2006;29(12):2644-9
12) Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with
a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial.
Diabetes Care 2006;29(1):44-50
13) Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous
glucose monitoring system: clinical decisions and glycemic control after its use in
pediatric type 1 diabetic subjects. Diabetes Care 2001;24(12):2030-4
14) Garg SK, Kelly WC, Voelmle MK, et al. Continuous home monitoring of glucose:
improved glycemic control with real life use of continuous glucose sensors in adult
subjects with type 1 diabetes. Diabetes Care 2007;30(12):3023-5
15) Chase HP, Beck RW, Xing D, et al. Continuous glucose monitoring in youth
with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation
continuous glucose monitoring randomized trial. Diabetes Technol Ther 2010;12(7
):507-15
16) Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved
metabolic control in pediatric patients with type 1 diabetes: a controlled crossover
study. Pediatrics 2003;111(5 Pt 1):933-8
17) De Block C, Manuel-y-Keenoy B, Van Gaal L. A review of current evidence with
continuous glucose monitoring in patients with diabetes. J Diabetes Sci Technol
2008;2(4):718-27
18) Vazeou A. Continuous blood glucose monitoring in diabetes treatment.
Diabetes Res Clin Pract 2011;93 (Suppl.1):S125-30
19) Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes. Diabetes
Res Clin Pract 2008;82 (Suppl.2):S118-21
20) Vaddiraju et al. Technologies for Continuous Glucose Monitoring: Current
Problems and Future Promises. J Diabetes Sci Technol 2010;4(6):1540-1562
[FTAB]
[TAB]
Photo:
http://photos.prnewswire.com/prnh/20121024/567690
[FTAB]
CONTACTO: Additional background information on 'Diabetes and continuousglucose monitoring' and 'C8 MediSensors and the Optical Glucose Monitor'are available from the European media contacts below.C8 MediSensors, Inc: Paul Zygielbaum, CEO, (+1) 408 622 2070; Fred Toney,CFO, (+1) 408 622 2050, Paul Connolly, VP Marketing & Sales, (+1) 408 7246453;European Media Contacts: UK: Aurora Healthcare Communications, Amy Noise /Rachel Terry, ((+44) 7720 592 689 / (+44) 7720 592 687, Germany: WaggenerEdstrom, Munich, Michaela Grandek, (+49) 89 628 1750, Spain: BerbesAssociados, Diana Zugasti / Sara Nieto,(+34) 91 563 23 00
